{"id":15370,"date":"2017-05-30T19:12:50","date_gmt":"2017-05-30T23:12:50","guid":{"rendered":"http:\/\/goldstocksforex.com\/?p=15370"},"modified":"2017-05-30T19:12:50","modified_gmt":"2017-05-30T23:12:50","slug":"weekly-investment-commentary-from-bob-doll-nuveen-2","status":"publish","type":"post","link":"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/","title":{"rendered":"Weekly Investment Commentary from Bob Doll | Nuveen"},"content":{"rendered":"<p>Key points from Bob Doll&#8217;s weekly investment summary:<\/p>\n<ul>\n<li>We believe U.S. economic growth should rebound in the second quarter and corporate earnings will remain solid.<\/li>\n<li>Investors remain uneasy about global macro conditions, but we believe the backdrop remains supportive for equities.<\/li>\n<li>We may be seeing a transition in global equity leadership from the United States to Europe and select emerging markets.<\/li>\n<\/ul>\n<p>Contrast this with <a href=\"http:\/\/goldstocksforex.com\/2017\/05\/30\/why-were-selling-all-shares-and-handing-cash-back-to-investors-philip-parker-livewire\/\">Philip Parker&#8217;s outlook at Altair Investments<\/a>.<\/p>\n<p>Read more at: <a href=\"https:\/\/www.nuveen.com\/Home\/Documents\/Default.aspx?fileId=58082\">Weekly Investment Commentary from Bob Doll | Nuveen<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key points from Bob Doll&#8217;s weekly investment summary: We believe U.S. economic growth should rebound in the second quarter and corporate earnings will remain solid. Investors remain uneasy about global macro conditions, but we believe the backdrop remains supportive for equities. We may be seeing a transition in global equity leadership from the United States &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Weekly Investment Commentary from Bob Doll | Nuveen&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[57,33,34],"tags":[],"class_list":["post-15370","post","type-post","status-publish","format-standard","hentry","category-stock-markets","category-uk-europe-countries-regions","category-us-canada-countries-regions"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor\" \/>\n<meta property=\"og:description\" content=\"Key points from Bob Doll&#8217;s weekly investment summary: We believe U.S. economic growth should rebound in the second quarter and corporate earnings will remain solid. Investors remain uneasy about global macro conditions, but we believe the backdrop remains supportive for equities. We may be seeing a transition in global equity leadership from the United States &hellip; Continue reading &quot;Weekly Investment Commentary from Bob Doll | Nuveen&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/\" \/>\n<meta property=\"og:site_name\" content=\"the patient investor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-30T23:12:50+00:00\" \/>\n<meta name=\"author\" content=\"ColinTwiggs\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ColinTwiggs\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/\"},\"author\":{\"name\":\"ColinTwiggs\",\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5\"},\"headline\":\"Weekly Investment Commentary from Bob Doll | Nuveen\",\"datePublished\":\"2017-05-30T23:12:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/\"},\"wordCount\":88,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#organization\"},\"articleSection\":[\"Stock Markets\",\"UK &amp; Europe\",\"US &amp; Canada\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/\",\"url\":\"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/\",\"name\":\"Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor\",\"isPartOf\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#website\"},\"datePublished\":\"2017-05-30T23:12:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/thepatientinvestor.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Weekly Investment Commentary from Bob Doll | Nuveen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/thepatientinvestor.com\/#website\",\"url\":\"https:\/\/thepatientinvestor.com\/\",\"name\":\"The Patient Investor\",\"description\":\"Smart. Strategic. Unfiltered. \",\"publisher\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/thepatientinvestor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/thepatientinvestor.com\/#organization\",\"name\":\"The Patient Investor Pty Ltd\",\"url\":\"https:\/\/thepatientinvestor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"width\":250,\"height\":250,\"caption\":\"The Patient Investor Pty Ltd\"},\"image\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\",\"https:\/\/www.instagram.com\/colin_thepatientinvestor\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5\",\"name\":\"ColinTwiggs\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"caption\":\"ColinTwiggs\"},\"url\":\"https:\/\/thepatientinvestor.com\/index.php\/author\/colin58s\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor","og_description":"Key points from Bob Doll&#8217;s weekly investment summary: We believe U.S. economic growth should rebound in the second quarter and corporate earnings will remain solid. Investors remain uneasy about global macro conditions, but we believe the backdrop remains supportive for equities. We may be seeing a transition in global equity leadership from the United States &hellip; Continue reading \"Weekly Investment Commentary from Bob Doll | Nuveen\"","og_url":"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/","og_site_name":"the patient investor","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61572934660810","article_published_time":"2017-05-30T23:12:50+00:00","author":"ColinTwiggs","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ColinTwiggs"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/#article","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/"},"author":{"name":"ColinTwiggs","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5"},"headline":"Weekly Investment Commentary from Bob Doll | Nuveen","datePublished":"2017-05-30T23:12:50+00:00","mainEntityOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/"},"wordCount":88,"commentCount":0,"publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"articleSection":["Stock Markets","UK &amp; Europe","US &amp; Canada"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/","url":"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/","name":"Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/#website"},"datePublished":"2017-05-30T23:12:50+00:00","breadcrumb":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thepatientinvestor.com\/"},{"@type":"ListItem","position":2,"name":"Weekly Investment Commentary from Bob Doll | Nuveen"}]},{"@type":"WebSite","@id":"https:\/\/thepatientinvestor.com\/#website","url":"https:\/\/thepatientinvestor.com\/","name":"The Patient Investor","description":"Smart. Strategic. Unfiltered. ","publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thepatientinvestor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/thepatientinvestor.com\/#organization","name":"The Patient Investor Pty Ltd","url":"https:\/\/thepatientinvestor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","width":250,"height":250,"caption":"The Patient Investor Pty Ltd"},"image":{"@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61572934660810","https:\/\/www.instagram.com\/colin_thepatientinvestor"]},{"@type":"Person","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5","name":"ColinTwiggs","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","caption":"ColinTwiggs"},"url":"https:\/\/thepatientinvestor.com\/index.php\/author\/colin58s\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p9tQ4n-3ZU","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":14360,"url":"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/","url_meta":{"origin":15370,"position":0},"title":"Weekly Investment Commentary from Bob Doll | Nuveen","author":"ColinTwiggs","date":"October 17, 2016","format":false,"excerpt":"From Bob Doll: Equities may struggle until corporate earnings improve. For the past 18 months, equities have been able to make modest gains despite declining corporate profits. This has largely been due to highly accommodative monetary policy and central banks\u2019 willingness to engage in new easing measures. Additionally, investors have\u2026","rel":"","context":"In &quot;Stock Markets&quot;","block_context":{"text":"Stock Markets","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/stock-markets\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":12935,"url":"https:\/\/thepatientinvestor.com\/index.php\/2016\/03\/09\/weekly-investment-commentary-from-bob-doll-nuveen-investments\/","url_meta":{"origin":15370,"position":1},"title":"Bob Doll: It May Take Better News for the Rally to Continue","author":"ColinTwiggs","date":"March 9, 2016","format":false,"excerpt":"From Bob Doll at Nuveen Investments: It May Take Better News for the Rally to Continue Financial markets appear to be normalizing in recent weeks after the risk asset rout that started the year. We would caution, however, that market improvements have come about because the news has become less\u2026","rel":"","context":"In &quot;Stock Markets&quot;","block_context":{"text":"Stock Markets","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/stock-markets\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":14851,"url":"https:\/\/thepatientinvestor.com\/index.php\/2017\/02\/21\/we-are-growing-less-positive-but-not-negative-toward-equities-bob-doll\/","url_meta":{"origin":15370,"position":2},"title":"We Are Growing Less Positive (But Not Negative) Toward Equities | Bob Doll","author":"ColinTwiggs","date":"February 21, 2017","format":false,"excerpt":"Great headline from Bob Doll (Nuveen Investments) latest newsletter. \"....we think the easy gains for equities are in the rearview mirror and we are growing less positive toward the stock market. We do not believe the current bull market has ended, but the pace and magnitude of the gains we\u2026","rel":"","context":"In &quot;Stock Markets&quot;","block_context":{"text":"Stock Markets","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/stock-markets\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":14017,"url":"https:\/\/thepatientinvestor.com\/index.php\/2016\/08\/22\/us-equity-prices-bob-doll\/","url_meta":{"origin":15370,"position":3},"title":"US equity prices | Bob Doll","author":"ColinTwiggs","date":"August 22, 2016","format":false,"excerpt":"Bob Doll's view on equities: Equity indices have again hit new records, but we believe fundamental changes may be necessary for prices to continue advancing strongly. Specifically, earnings would have to improve further and\/or investor flows would have to turn notably toward stocks. Neither is out of the question, but\u2026","rel":"","context":"In &quot;Stock Markets&quot;","block_context":{"text":"Stock Markets","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/stock-markets\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":15409,"url":"https:\/\/thepatientinvestor.com\/index.php\/2017\/06\/05\/upside-possibilities-look-more-likely-than-downside-risks-bob-doll\/","url_meta":{"origin":15370,"position":4},"title":"Upside Possibilities Look More Likely Than Downside Risks | Bob Doll","author":"ColinTwiggs","date":"June 5, 2017","format":false,"excerpt":"From Bob Doll's latest weekly update: Investors remain highly focused on global political issues. Emmanuel Macron\u2019s victory in France has reduced some political risk in Europe, but investors are growing increasingly skeptical about President Trump\u2019s ability to deliver on his pro-growth agenda. The growing scrutiny over White House ties to\u2026","rel":"","context":"In &quot;Economy&quot;","block_context":{"text":"Economy","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/economy\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":15617,"url":"https:\/\/thepatientinvestor.com\/index.php\/2017\/07\/21\/weekly-top-themes-from-bob-doll-nuveen\/","url_meta":{"origin":15370,"position":5},"title":"Weekly Top Themes from Bob Doll | Nuveen","author":"ColinTwiggs","date":"July 21, 2017","format":false,"excerpt":"U.S. monetary policy should remain equity-market friendly. In her comments last week, Janet Yellen stated that the neutral rate for the fed funds rate is \u201ccurrently quite low,\u201d and rates would not have to rise much more to become neutral. In our view, a neutral fed funds rate is closer\u2026","rel":"","context":"In &quot;Banks &amp; Interest Rates&quot;","block_context":{"text":"Banks &amp; Interest Rates","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/economy\/the-fed-banks-interest-rates\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/15370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/comments?post=15370"}],"version-history":[{"count":0,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/15370\/revisions"}],"wp:attachment":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/media?parent=15370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/categories?post=15370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/tags?post=15370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}